Table 1.
Class | Application | Azole | Brand | Mycosis | Notes | Ref. |
---|---|---|---|---|---|---|
Imidazole | Topical | butoconazole | Gynazole-1, Mycelex-3 | uncomplicated and recurrent vaginal candidiasis | [65] | |
climbazole | Squaphane, Pitiren | dandruff and seborrhoeic dermatitis caused by Malassezia sp. | [66] | |||
clotrimazole † | Lotrimin | oral and vaginal candidiasis, and tinea versicolor, cruris and pedis | WHO Essential Medicine | [66,67] | ||
eberconazole | Ebernet | cutaneous candidiasis and dermatophytosis | Approved in EU in 2015 | [68] | ||
econazole | Spectrazole, Ecostatin | tinea pedis and cruris, vaginal candidiasis | Also repels clothes moths | [69] | ||
flutrimazole | Flusporan, Topiderm | cutaneous dermatophytosis including tinea pedis | [70] | |||
isoconazole | Icaden, Travogen | tinea pedis and vaginal candidiasis | Effective against Gram-positive bacteria | [71] | ||
ketoconazole † | Nizoral | seborrhoeic dermatitis, dandruff, tinea and cutaneous candidiasis | Also systemic | [72] | ||
luliconazole | Luzu | tinea pedis and cruris and other dermatophytoses | FDA-approved in 2013 | [73] | ||
miconazole † | Monistat, Desenex | dermatophytosis and cutaneous, oral and vaginal candidiasis | WHO Essential Medicine | [74] | ||
oxiconazole | Oxistat, Oxizole | dermatophytoses and cutaneous candidiasis | [75] | |||
sertaconazole | Ertaczo, Dermofix | tinea pedis and vaginal candidiasis | Also anti-inflammatory and anti-pruritic | [76,77] | ||
sulconazole | Exelderm | dermatophytoses | Also anti-carpet beetle | [78,79] | ||
tioconazole | Vagistat-1 | onychomycosis, dermatophytoses and vaginal candidiasis | Also called thioconazole | [80] | ||
Systemic | ketoconazole | Nizoral (oral) | mycoses caused by Candida, Histoplasma and Coccidioides | Systemic use for extreme cases only | [81] | |
Triazole | Topical | efinaconazole | Jublia, Clenafin | onychomycosis | Low cure rate, but higher than other drugs | [82] |
fluconazole † | Diflucan | dermatophytoses and cutaneous candidiasis | WHO Essential Medicine, more commonly systemic | [21] | ||
terconazole | Terazol | acute and chronic vaginal candidiasis | [83] | |||
Systemic | fluconazole † | Diflucan | candidiasis, cryptococcosis, histoplasmosis, blastomycosis | WHO Essential Medicine, oral or intravenous | [21] | |
fosfluconazole | Prodif | prophylaxis in the immunocompromised | Fluconazole prodrug | [84,85] | ||
fosravuconazole | Nailin | onychomycosis | Ravuconazole prodrug | [86] | ||
isavuconazonium | Cresemba | mucormycosis and invasive aspergillosis | Isavuconazole prodrug | [35,87] | ||
itraconazole † | Sporanox, Orungal | aspergillosis, histoplasmosis, coccidioidomycosis and blastomycosis | WHO Essential Medicine | [48,88] | ||
posaconazole | Noxafil, Posanol | invasive candidiasis, aspergilosis, mucormycosis and scedosporiosis | FDA-approved in 2006 | [89] | ||
voriconazole † | Vfend | aspergillosis, candidiasis, penicilliosis, histoplasmosis and fusariosis | WHO Essential Medicine | [90] |
† Most commonly prescribed azole antifungals. Other azole antifungals no longer on the market include ravuconazole, a triazole similar to voriconazole which was discontinued after Phase-III clinical trials and the thiazole abafungin, which is no longer available [91].